By Kamal Choudhury March 26 (Reuters) - Wave Life Sciences shares plunged 58% on Thursday after a higher dose of its experimental obesity drug failed to show a clear improvement at reducing a ...

Shares of Kodiak Sciences surged 68.6% to their highest in more than ​four years on Thursday after the drug developer's ...

The deal brings Exact Sciences' flagship screening test for colorectal cancer, Cologuard, under Abbott's umbrella.

Anavex shares crash as the EMA indicates it won’t issue a positive opinion on its candidate Alzheimer’s drug. Here’s why long ...

Shares of Kodiak Sciences shot higher after the company disclosed what it called positive results from a late-stage study of its treatment for diabetic retinopathy, a progressive disease that occurs ...

Wave Life Sciences shares plunged >50% after Phase 1 INLIGHT data for WVE-007 showed <1% placebo-adjusted weight loss at six ...

Kodiak Sciences Inc. reports fourth-quarter 2025 results Thursday, as the pre-commercial biotech seeks to narrow losses while advancing three late-stage drug candidates toward potential approval.

Loomis Sayles, an investment management company, released its fourth-quarter 2025 investor letter for “Small Cap Growth Fund” ...

Achieve exceeded long-term safety study requirements and secured a manufacturing partnership, positioning for a potential 1H ...

Life sciences mergers and acquisitions surged back in force in 2025, as pharmaceutical and med-tech companies moved aggressively to shore up pipelines and offset looming revenue losses, according to ...

In life sciences, enterprise value only emerges when generative AI is treated as a business capability and embedded into ...

Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...